WIM
Woodford Investment Management Portfolio holdings
AUM
$310M
This Quarter Return
+26.57%
1 Year Return
-17.41%
3 Year Return
-27.69%
5 Year Return
+67.02%
10 Year Return
–
AUM
$2.47B
AUM Growth
+$2.47B
(+16%)
Cap. Flow
-$9.9M
Cap. Flow
% of AUM
-0.4%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
3
Reduced
3
Closed
–
Top Buys
| 1 |
Biogen
BIIB
|
$47.1M |
| 2 |
Gilead Sciences
GILD
|
$38.5M |
| 3 |
Theravance Biopharma
TBPH
|
$24.4M |
| 4 |
Alkermes
ALKS
|
$635K |
Top Sells
| 1 |
RAI
Reynolds American Inc
RAI
|
$80.8M |
| 2 |
AbbVie
ABBV
|
$39.5M |
| 3 |
Prothena Corp
PRTA
|
$180K |
Sector Composition
| 1 | Healthcare | 85.5% |
| 2 | Consumer Staples | 14.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
AbbVie
ABBV
$372B
| $696M | 28.12% | 11,029,800 -627,000 | -5% | -$39.5M |
|
|
2
Prothena Corp
PRTA
$441M
| $617M | 24.96% | 10,301,751 -3,000 | -0% | -$180K |
|
|
RAI
3
DELISTED
Reynolds American Inc
RAI
| $359M | 14.5% | 7,608,324 -1,714,139 | -18% | -$80.8M |
|
|
4
Alkermes
ALKS
$4.78B
| $355M | 14.35% | 7,549,033 +13,500 | +0.2% | +$635K |
|
|
5
Theravance Biopharma
TBPH
$699M
| $341M | 13.78% | 9,407,137 +673,500 | +8% | +$24.4M |
|
|
6
Biogen
BIIB
$19.4B
| $53.4M | 2.16% | 170,430 +150,430 | +752% | +$47.1M |
|
|
7
Gilead Sciences
GILD
$140B
| $38.5M | 1.56% | +486,800 | New | +$38.5M |
|
|
NWBO
8
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
| $14.1M | 0.57% | 25,915,937 | – | – |
|